NirA Is an Alternative Nitrite Reductase from Pseudomonas aeruginosa with Potential as an Antivirulence Target by Fenn, Samuel et al.
NirA Is an Alternative Nitrite Reductase from Pseudomonas
aeruginosa with Potential as an Antivirulence Target
Samuel Fenn,a Jean-Frédéric Dubern,a Cristina Cigana,b Maura De Simone,b* James Lazenby,a*Mario Juhas,c*
Stephan Schwager,c Irene Bianconi,b* Gerd Döring,d† Jonas Elmsley,a Leo Eberl,c Paul Williams,a Alessandra Bragonzi,b
Miguel Cámaraa
aNational Biofilms Innovation Centre, Nottingham University Biodiscovery Institute, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
bDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
cDepartment of Microbiology, Institute of Plant Biology, University of Zürich, Zürich, Switzerland
dInstitute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany
ABSTRACT The opportunistic pathogen Pseudomonas aeruginosa produces an arsenal
of virulence factors causing a wide range of diseases in multiple hosts and is difficult
to eradicate due to its intrinsic resistance to antibiotics. With the antibacterial pipeline
drying up, antivirulence therapy has become an attractive alternative strategy to the
traditional use of antibiotics to treat P. aeruginosa infections. To identify P. aeruginosa
genes required for virulence in multiple hosts, a random library of Tn5 mutants in
strain PAO1-L was previously screened in vitro for those showing pleiotropic effects in
the production of virulence phenotypes. Using this strategy, we identified a Tn5 mutant
with an insertion in PA4130 showing reduced levels of a number of virulence traits in
vitro. Construction of an isogenic mutant in this gene presented results similar to those
for the Tn5 mutant. Furthermore, the PA4130 isogenic mutant showed substantial
attenuation in disease models of Drosophila melanogaster and Caenorhabditis elegans
as well as reduced toxicity in human cell lines. Mice infected with this mutant demon-
strated an 80% increased survival rate in acute and agar bead lung infection models.
PA4130 codes for a protein with homology to nitrite and sulfite reductases.
Overexpression of PA4130 in the presence of the siroheme synthase CysG enabled its
purification as a soluble protein. Methyl viologen oxidation assays with purified PA4130
showed that this enzyme is a nitrite reductase operating in a ferredoxin-dependent
manner. The preference for nitrite and production of ammonium revealed that PA4130
is an ammonia:ferredoxin nitrite reductase and hence was named NirA.
IMPORTANCE The emergence of widespread antimicrobial resistance has led to the
need for development of novel therapeutic interventions. Antivirulence strategies
are an attractive alternative to classic antimicrobial therapy; however, they require
identification of new specific targets which can be exploited in drug discovery pro-
grams. The host-specific nature of P. aeruginosa virulence adds complexity to the dis-
covery of these types of targets. Using a sequence of in vitro assays and phylogeneti-
cally diverse in vivo disease models, we have identified a PA4130 mutant with
reduced production in a number of virulence traits and severe attenuation across all
infection models tested. Characterization of PA4130 revealed that it is a ferredoxin-
nitrite reductase and hence was named NirA. These results, together with attenua-
tion of nirA mutants in different clinical isolates, high level conservation of its gene
product in P. aeruginosa genomes, and the lack of orthologues in human genomes,
make NirA an attractive antivirulence target.
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P seudomonas aeruginosa is a genetically versatile opportunistic pathogen, able tocolonize and survive in multiple environments and hosts. This versatility underpins
the ability of P. aeruginosa to cause a wide range of infections, commonly affecting the
respiratory tract, burn wounds, urinary tract, bloodstream, cornea, skin, and soft tissue
(1). The majority of these infections are nosocomial, with infections in immunocompro-
mised hosts often life-threatening.
P. aeruginosa has gained notoriety as a member of the ESKAPE (Enterococcus fae-
cium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Enterobacter species) pathogens (2). These pathogens
are differentiated according to their clinical relevance and capacity to become multi-
drug resistant (MDR). Often treatment of P. aeruginosa is unsuccessful due to high lev-
els of intrinsic and acquired antimicrobial resistance with biofilm formation promoting
antimicrobial tolerance (3, 4).
Although carbapenem-resistant P. aeruginosa has been listed as “priority one” by
the World Health Organization for the development of new antimicrobials, no new
drugs with a novel mechanism of action against this organism have reached the mar-
ket in recent years (5). Hence, there is a pressing need for the discovery of novel alter-
native strategies to the traditional use of antibiotics to treat P. aeruginosa infections.
Antivirulence therapeutic approaches offer an attractive alternative strategy for devel-
oping drugs with high specificity and narrow spectra as they reduce the illness caused
by the pathogen (“pathogen limitation”) instead of reducing pathogen burden directly
(“pathogen elimination”) (6).
In recent years, vast progress has been made on the identification of P. aeruginosa
virulence factors, unravelling the mechanisms they employ to cause disease and devel-
oping inhibitors which can inactivate them (7–12). While these studies have uncovered
numerous promising small virulence inhibitor molecules, none has yet made it to the
clinic. This has been influenced by many different factors, including the reliance on a
single disease model, potential target conservation within the microbiota, a lack of
understanding of target functionality, and the inability to define success when search-
ing for inhibitors (13).
The sequencing of the first P. aeruginosa genome in 2000 revealed that the PAO1
strain sequenced (PAO1-UW) has a genome size of 6.3 Mbp and contains 5,570 open
reading frames, making it the largest bacterial genome sequenced at the time (14).
This large genome underpins the extensive metabolic and regulatory network provid-
ing P. aeruginosa with the genetic versatility to colonize multiple environments, hosts,
and host sites. Besides, with the function of only 22.7% of P. aeruginosa genes experi-
mentally demonstrated and close to 2,000 genes without functional annotation (15),
there is still a large amount of information missing with regard to the mechanisms by
which this organism causes disease, and potentially a vast array of novel P. aeruginosa
virulence targets remains to be discovered.
Early studies suggested that virulence mechanisms employed by P. aeruginosa to
infect phylogenetically diverse hosts are remarkably well conserved. Comparison of
infection mechanisms in the plant Arabidopsis thaliana and mice revealed that P. aeru-
ginosa uses a shared subset of virulence genes to provoke disease (16). The conserved
nature of P. aeruginosa virulence suggested that use of a single disease model is suffi-
cient to dissect P. aeruginosa virulence in all hosts (17), with various studies utilizing
the nematode Caenorhabditis elegans (18), fruit fly Drosophila melanogaster (19), silk-
worm Bombyx mori (20), Galleria mellonella larvae (21), and zebrafish embryos (22).
However, limitations of these studies are related to the impact of virulence in multihost
system and the number of P. aeruginosa strains tested.
A study performed by our group combining whole-genome transposon mutagene-
sis with a cascade of in vitro and in vivo infection models uncovered the host-specific
nature of P. aeruginosa virulence (23). This revealed a remarkably low overlap in viru-
lence factor requirements between different models, suggesting that many of the viru-
lence factors identified with single model studies may not represent virulence factors
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required during human disease (23). Given the broad range of clinical manifestations
exhibited by P. aeruginosa infections, it stands to reason that virulence genes identified
as attenuated in multiple models are more likely to be both relevant to human disease
and at multiple infection sites, representing promising antivirulence targets.
This study builds upon the successful whole-genome transposon mutant screening
to identify novel P. aeruginosa virulence target genes (23). Here, we describe the identi-
fication of an additional mutant from this library on a yet uncharacterized gene of P.
aeruginosa, PA4130, exhibiting attenuation in all infection models tested. Functional
characterization revealed that PA4130 encodes an assimilatory nitrite reductase with a
potential role in nitrogen source metabolism during P. aeruginosa pathogenesis. The
attenuation in all disease models tested and the lack of human homologues make this
nitrite reductase a promising antivirulence therapeutic target.
RESULTS
Isolation of an P. aeruginosa mutant attenuated in multiple virulence factor
production. To isolate novel virulence genes, a transposon (Tn5) insertion library was
generated in a wild-type PAO1-L strain (23). A total of 57,360 individual colonies were
picked and screened for pleiotropic attenuation in virulence phenotypes (reduced
swarming and exoprotease and pyocyanin production) (23). Using the same screening
approach, in the current study, a further transposon mutant (PAJD21) was isolated
from the library. This mutant displayed reduced levels of pyocyanin and pyoverdine
production as well as decreased swarming motility, with twitching, swimming, prote-
ase, and elastase activity being unaffected compared to that of the wild type (Fig. 1A
to D; see also Table S1 in the supplemental material). Nucleotide sequence analysis of
the Tn5-flanking region showed that the transposon had inserted into PA4130, encod-
ing a hypothetical protein with homology to nitrite and sulfite reductases, and forming
a predicted operon with PA4129 (Fig. 1E). To ensure the attenuation in virulence traits
observed was not due a polar effect on PA4129, located in the same predicted tran-
scriptional unit as PA4130, in-frame deletion mutants of both PA4130 and PA4129
were constructed to generate strains PAJD25 and PASF06, respectively. These isogenic
mutants showed no growth differences in either lysogeny broth (LB) or artificial spu-
tum medium (ASM) in relation to the parental strain (see Fig. S2 in the supplemental
material).
The PAJD25 strain showed phenotypes similar to those of the Tn5 mutant PAJD21,
with pyocyanin and pyoverdine reduced in both LB and ASM and swarming motility
also impeded. Chromosomal complementation of PAJD25 with PA4130 restored pyo-
cyanin and swarming motility to wild-type levels, with partial restoration of pyoverdine
production (Fig. 1A to D). In contrast, the PA4129 deletion mutant PASF06 did not
show any significant alterations in the virulence-related phenotypes (Table S3). This
demonstrates that the phenotypes observed are specific to the mutation of PA4130.
When identifying new virulence targets, it is paramount to ensure they are con-
served in a wide range of strains. To establish this, a nucleotide BLAST search of
PA4130 against the NCBI P. aeruginosa taxonomic identifier database (taxid 287)
revealed that this hypothetical protein is highly conserved, with 363/367 of the avail-
able genomes encoding a PA4130 orthologue. To determine whether PA4130 has a
similar role in the virulence of P. aeruginosa strains from different sublines, in-frame
PA4130 deletion mutants were created in the clinical isolates PA7 Bo599, PA14
AUS471, and LESB58 PA-W39. Deletion of PA4130 across all these strains resulted in a
similar attenuation for both pyocyanin production and swarming motility, while prote-
ase production and growth remained unaffected, validating the results obtained for
PAJD21 and PAJD25 (Fig. 2A to C and Table S4). In contrast, reduction in pyoverdine
production was not conserved with no consistent pattern emerging between strains
(Table S4). The similar phenotypes observed in the PA4130 deletion strains across phy-
logenetically diverse P. aeruginosa strains confirms PA4130 is not a PAO1-L specific vir-
ulence determinant. This supported the use of PAO1-L and the derived strain PAJD25
as representative strains to further characterize the role of PA4130 in virulence.
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PA4130 is required for full virulence in C. elegans and D. melanogaster. To es-
tablish whether the decrease in virulence trait production observed in the PA4130 de-
letion mutant PAJD25 in vitro also results in disease attenuation in vivo, the D. mela-
nogaster and C. elegans nonmammalian infection models previously used for P.
aeruginosa infection studies were initially used. In both disease models, the PAJD25
(DPA4130) mutant showed an attenuated survival rate compared to that of the iso-
genic wild-type PAO1-L (Fig. 3). For C. elegans, PAJD25 virulence was severely attenu-
ated with a 57% increase in survival at 72 h postinfection (Fig. 3A). In the case of D.
FIG 1 In vitro phenotypic characterization of P. aeruginosa PAO1-L virulence factor production versus
PA4130 mutants. The transposon mutant PAJD21 (PA4130::Tn5), the PA4130 in-frame deletion mutant
PAJD25, and the complemented mutant PAJD25 pCTX4130 were used in these experiments. (A)
Pyocyanin levels determined in supernatants from cultures grown for 8 and 20 h in LB using a
colorimetric assay. (B) Pyoverdine levels determined in supernatants from cultures grown for 8 and
24 h in modified artificial sputum medium using a colorimetric assay. A405/600, absorbance at 405
and 600 nm. (C and D) Swarming motility surface coverage measurements (C) and images (D); cells
were inoculated from a 16-h LB culture onto swarming plates containing 0.5% agar and incubated at
37°C for 16 h. (E) Diagram displaying operon structure and transcriptional start sites of PA4129-
PA4130 and PA4131- PA4132 with the PAJD21 Tn5 insertion site indicated by the red arrow. Data
were collated from three independent experiments with at least three replicates each. Values that are
significantly different by Dunnett’s multiple-comparison test are indicated by asterisks as follows: **, P
, 0.01; ****, P , 0.0001.
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melanogaster, PAJD25 killing was delayed with a 40% increase in survival at 18 h post-
infection, although by 22 h, this difference was negligible (Fig. 3A).
Deletion of PA4130 results in reduced cytotoxicity, cellular invasion, and IL-8
production in A549 human lung epithelial cell line. A previous screening of the Tn5
mutant library screening by Dubern and colleagues (23) suggested that attenuation
using in vitro assays and invertebrate infection models does not translate into mamma-
lian models. To establish whether this is the case for the PA4130 mutant, the PAJD25
(DPA4130) strain was tested on the A549 pulmonary cell line for cytotoxicity, invasion,
and interleukin 8 (IL-8) production (Fig. 4). Cytotoxicity of the PAJD25 supernatant was
drastically reduced compared to strain PAO1-L, which is in line with the reduced levels
of secreted pyocyanin (Fig. 1A and 4A). Furthermore, invasion of A549 epithelial cells
was reduced in strain PAJD25, with IL-8 production also reduced compared to wild-
type strain PAO1-L (Fig. 4B and C).
Deletion of PA4130 reduces lethality of P. aeruginosa in acute and agar bead
murine infection models. The impact of a PA4130 mutation on P. aeruginosa virulence
was initially assessed by determining the survival curve of PJD25 (DPA4130) in an acute
FIG 2 In vitro phenotypic characterization of virulence factor production for PA4130 orthologue
mutants in PA7 Bo599, PA14 AUS471, and LESB58 PA-W39. (A) Pyocyanin levels determined in
supernatants from cultures grown for 8 and 20 h in LB using a colorimetric assay. (B and C) Swarming
motility surface coverage measurements (B) and images (C); cells were inoculated from a 16-h LB
culture onto swarming plates containing 0.5% agar and incubated at 37°C for 20 h. Data were
collated from two independent experiments with at least four replicates. Values that are significantly
different by Tukey’s multiple-comparison test are indicated by asterisks as follows: *, P , 0.05, **, P ,
0.01, ****, P , 0.0001.
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lung infection model in C57BL/6NCrlBR mice using an infection dose of 5 106 CFU. A
survival rate of 80% was shown at 72 h postinfection in contrast to strain PAO1-L which
did not show any survival after 36 h (Fig. 5).
The effect of the PA4130 mutation was then tested in an agar bead infection model
to monitor initial colonization and systemic spread. C57BL/6NCrlBR mice were infected
with a 2 106 CFU dose of either strain PAO1-L or PAJD25. At 18 h postinfection, 20%
of PAO1-L-infected mice and 80% of PAJD25-infected mice survive. By 36 h, 80% of
PAJD25-challenged mice still survive while PAO1-L-infected mice exhibit no survival
(Fig. 6A). The reduction in mortality was confirmed by the reduced CFU recovery from
the lung, liver, and spleen of the mutant compared to the wild type (Fig. 6B to D).
Clearance or reduced CFU in the lung of PAJD25-infected mice demonstrates that
interruption of PA4130 interferes with colonization. This impaired colonization results
in reduced systemic spread with no PAJD25 detected in the spleen or liver in all but
one sample (Fig. 6B to D).
Overall, the data presented demonstrate that PA4130 plays a role in P. aeruginosa
survival and virulence in multiple models of infection, suggesting that PA4130 is not a
model-specific virulence gene.
Purification of PA4130 reveals characteristics of a possible nitrite or sulfite
reductase. Amino acid sequence analysis showed that PA4130 has an amino acid simi-
larity of 21% with the Escherichia coli CysI sulfite reductase hemoprotein subunit and
that no protein homologues are encoded within the human genome. Alignment of the
FIG 4 Cytotoxicity, IL-8 release, and invasion of A549 cells following infection with either strain PAO1-L or
PAJD25. (A) Cytotoxicity assayed with Syto13/propidium iodine (PI) viability staining. WT, wild type. (B) IL-8
released quantified by enzyme-linked immunosorbent assay (ELISA) following infection. (C) Invasion quantified
using an antibiotic (polymyxin B) exclusion assay. Data from three independent experiments are expressed as
means 6 standard errors of means (SEM) (error bars). **, P , 0.01 by Student’s t test.
FIG 3 Survival of strain PAO1-L versus strain PAJD25 in nonmammalian models. (A) 72-h lethality
curve in the C. elegans infection model. (B) 22-h lethality curve in D. melanogaster. Both models
demonstrated clear attenuation with increased survival of PAJD25 in C. elegans at all time points. D.
melanogaster exhibited a delay in killing with increased survival at earlier time points; however, by
22 h, both PAO1-L and PAJD25 showed almost complete killing. The results presented display the
mean values from three independent experiments. *, P , 0.032, ****, P , 0.0001 log rank Mantel-Cox
test.
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PA4130 amino acid sequence with the E. coli MG1655 CysI, Mycobacterium tuberculosis
H37RV NirA, and Spinacea oleracea (spinach) NirA, using ClustalW, revealed the pres-
ence of conserved residues indicative of 4Fe-4S and siroheme prosthetic group bind-
ing sites (Fig. S2). Initial expression and purification attempts yielded insoluble, non-
functional PA4130. Prosthetic group limitation was hypothesized to limit soluble
PA4130 expression. Cooverexpression of iron-sulfur cluster biogenesis or siroheme syn-
thesis proteins has been demonstrated to increase expression of functional enzymes
incorporating these prosthetic groups (24, 25). PA4130 was subsequently cooverex-
pressed in the presence of the siroheme synthase CysG, yielding a 20-fold increase in
soluble PA4130 expression. PA4130 was purified to homogeneity with a combination
of immobilized metal affinity chromatography and chitin column chromatography,
while size exclusion chromatography revealed PA4130 is a monomer in solution
FIG 5 Survival curve of C57BL/6NCrlBR mice infected with strains PAO1-L and PAJD25 in an acute
lung infection model. At 36 h, PAJD25 exhibits a 90% increase in survival compared to PAO1-L, with
80% of PAJD25-infected mice surviving past 96 h. ****, P , 0.0001 by log rank Mantel-Cox test.
FIG 6 Virulence of strains PAO1-L and PAJD25 in an agar bead murine lung infection model of
colonization in C57BL/6NCrlBR mice. (A to D) Survival curve (A), CFU recovery from lung (B), CFU
recovery from the liver (C) and CFU recovery from the spleen at 36 h postinfection (D). Strain PAJD25
exhibits a significant increase in survival at 36 h postinoculation with a CFU recovery 3 log units
lower than that of strain PAO1-L in the lungs. PAO1-L infection progresses to the liver and spleen
within 36 h, while PAJD25 infection does not proceed to the liver and spleen as indicated by the
absence of CFU recovery in all but one sample. ****, P , 0.0001 by log rank Mantel-Cox test for
survival curve. *, P , 0.05; **, P , 0.01 by Student’s t test for CFU recovery.
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(Fig. S3). Spectroscopic characterization of the soluble PA4130 protein confirmed the
presence of peaks at 382 nm, 587 nm, and 712 nm, characteristic of siroheme and
4Fe-4S incorporation into nitrite/sulfite reductase hemoprotein subunits (data not
shown).
PA4130 codes for an assimilatory nitrite reductase operating in a ferredoxin-
dependent manner. Nitrite or sulfite reductases catalyze the six-electron reduction of
nitrite or sulfite to ammonium or hydrogen sulfide, respectively. These enzymes
require an electron acceptor and donor to complete the electron transport chain. The
electron acceptor is nitrite or sulfite with the electron donor being either NADPH,
NADH, or ferredoxin.
To determine the native electron acceptor, we used a reduced methyl viologen
(MV) reductase assay, which spectrophotometrically tracks the artificial electron donor
oxidation in the presence of nitrite or sulfite as the possible electron acceptor for
PA4130 (26). Our data show that PA4130 was able to oxidize MV only in the presence
of nitrite with minimal oxidation occurring in the presence of sulfite (Fig. 7A). These
results confirm that PA4130 functions as a nitrite reductase and hence participates in
the nitrate reduction pathway.
To identify the native electron donor used by PA4130, the same assay as described
above was carried out with the alternative electron donors NADPH1FAD and reduced
spinach ferredoxin, with the remaining nitrite quantified using Griess diazotization.
Tracking of the remaining nitrite revealed that reduction occurs only in the presence of
MV and reduced ferredoxin while minimal reduction occurs with NADPH plus FAD
(Fig. 7B). This observation is in agreement with a study by Frangipani and colleagues
showing that increased expression of both PA4130 and the ferredoxin:NADP1 reduc-
tase fprA are induced by cyanogenesis in P. aeruginosa (27). This suggests that the role
of FprA is to reduce ferredoxins, using NADPH as an electron donor, ensuring a supply
of reduced ferredoxin for PA4130 to derive electrons for nitrite reduction.
The nitrite reductase cognate pathways can be assigned via the end reaction prod-
uct. Nitric oxide (NO)-forming nitrite reductases participate in the dissimilatory denitri-
fication pathway, while ammonium (NH41)-producing reductases are part of either
assimilatory or dissimilatory nitrite reduction to ammonium (DNRA) pathways (Fig. 8)
(28). P. aeruginosa genes encode three structurally distinct nitrite reductases, the NO-
forming denitrification reductase NirS, NH41-forming NirBD, and unassigned PA4130.
Conserved domain analysis using DELTA-BLAST suggests that PA4130 resembles an
ammonium-producing nitrite reductase. This was confirmed with an ammonium pro-
duction assay following nitrite reduction using reduced ferredoxin as an artificial elec-
tron donor (Fig. S4).
Together, these data indicate that PA4130 codes for an ammonium-producing, fer-
redoxin- and siroheme-dependent, nitrite reductase, which participates in the nitrate
FIG 7 PA4130-mediated reduction assays for native electron acceptor and donor determination. (A)
Methyl viologen oxidation assay in the presence of the electron acceptors nitrite and sulfite. Reduced
MV is oxidized only in the presence of nitrite, indicating PA4130 is a nitrite reductase. (B) Nitrite
reduction assay using MV, reduced ferredoxin, and NADPH as electron donors. The remaining nitrite
was quantified by Griess diazotization, with nitrite reduction occurring in the presence of MV and
reduced ferredoxin.
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reduction cycle. We propose that PA4130 be renamed NirA to fit with current
nomenclature.
DISCUSSION
In a previous study, we aimed to identify novel genes required for virulence in P.
aeruginosa using a multihost screening strategy with the ultimate goal of discover-
ing novel antivirulence targets (23). Using the same strategy we have identified, a
new Tn5 mutation in PA4130 which is attenuated in multiple virulence factor pro-
duction. One limitation previously identified with this screening strategy (23) was
the use of a single strain of P. aeruginosa, as there can be significant variations
between the virulence of different strains, potentially leading to the identification of
strain-specific virulence factors (29). This problem was circumvented by generating
PA4130 orthologue deletion mutants in phylogenetically distinct P. aeruginosa
strains covering the major phylogenetic groups identified by Freschi and colleagues
(30). This revealed a conserved role of PA4130 in virulence factor production with
pyocyanin production and swarming motility being impaired across all mutants.
Further screening revealed attenuation of a PA4130 mutant across all disease mod-
els tested in this study, confirming that PA4130 is not a disease model-specific viru-
lence determinant and is likely to play a key role in survival during human infection.
This makes PA4130 a promising target which can be taken forward for functional
and structural characterization with a view to develop novel virulence inhibitors
against this opportunistic pathogen.
Characterization of the predicted gene product of PA4130 showed an assimila-
tory ferredoxin-dependent nitrite reductase likely involved in nitrate and wider cen-
tral nitrogen metabolism. Hence, it has subsequently been named nirA. Previous
studies have also detected various carbon and nitrogen metabolic genes as essential
for full virulence, since infection is associated with significant metabolic changes
(23, 31, 32). Inhibiting adaptation to carbon and nitrogen sources or attenuating the
ability to protect from nitrative stress during infection could prove an attractive anti-
virulence strategy with metabolic dysregulation having knockdown effects on multi-
ple cellular cycles.
Nitrogen source metabolism is essential for the survival of P. aeruginosa in diverse
environments enabling amino acid synthesis, carbon source utilization, and respiration
in the absence of oxygen (31). A key element to nitrogen source metabolism is the
reduction of nitrate. P. aeruginosa nitrate metabolism is a highly branched and
FIG 8 Genetic and biochemical pathways involved in nitrate reduction. This highly branched process
is divided into three primary pathways: assimilatory and dissimilatory nitrite reduction to ammonium
(DNRA) and dissimilatory denitrification. The presence of multiple pathways enables multiple
biological functions to be performed with amino acid synthesis, detoxification, energy generation,
and conservation key to survival in diverse environments.
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interlinked process with three main pathways, dissimilatory denitrification, dissimila-
tory nitrate reduction to ammonium (DNRA), and assimilatory nitrate reduction to am-
monium (Fig. 8) (28, 33).
Dissimilatory denitrification in P. aeruginosa reduces nitrate to gaseous dinitrogen,
coupling reduction to generation of a proton gradient. This facilitates respiration in the
absence of oxygen. The assimilatory pathway is dedicated to biosynthesis, with the
assimilatory nitrate reductase (NasC) and assimilatory nitrite reductase (NirBD) produc-
ing nitrogen in the form of ammonium. DNRA differs, requiring the respiratory nitrate
reductases NarGHI or NapABC to enable energy generation/conservation (28, 33) while
simultaneously maintaining intracellular level of nitrogen via the production of
ammonium.
The NirA production of ammonium in vitro suggests that it participates in either
assimilatory or DNRA with potential implications in amino acid biosynthesis, energy
conservation, detoxification, and maintenance of the intracellular redox environment
(28, 34). However, determining the exact role NirA plays during virulence is compli-
cated by the fact that P. aeruginosa genes code for two additional producing nitrite re-
ductases, nitric oxide-forming NirS and ammonium-forming NirBD.
NirS is a component of the dissimilatory denitrification pathway and reduces ni-
trite to nitric oxide (NO). Various components of the dissimilatory nitrate reduction
pathway have been demonstrated to be attenuated for virulence, with deletion of
NirS in PA14 reported to be avirulent in C. elegans and the THP-1 human monocyte
cell line (35, 36). However, these NirS-dependent phenotypes have been attributed
to production of NO which modulates type III secretion system expression (36).
Since NirA is an NH4-forming nitrite reductase, it participates in a separate part of
the nitrate reductase pathway (Fig. 8), with the resulting phenotypes independent
of NO production.
Although NirBD and NirA perform the same molecular function, they are differen-
tially regulated. nirBD-PA1779(nasC)-cobA are under the control of the RpoN nitrogen
utilization sigma factor, with NtrC and NasT acting as transcriptional activators.
Expression occurs under low nitrogen availability in the presence of nitrate and nitrite
(37). In contrast, NirA expression is under the control of cyanogenesis and is involved
in protecting cells from HCN self-intoxication alongside PA4129-34 and cioAB by a yet
undefined mechanism (27).
The role played by these ammonium-forming nitrite reductases during pathogene-
sis has largely remained unexplored in vivo with the exception of M. tuberculosis, where
induction of nirBD is required for survival in human macrophages during hypoxia (38).
Animals and plants produce reactive nitrogen species (RNS) in response to diverse bac-
terial infections (39). Host-derived RNS originate from inducible and constitutively
expressed nitric oxide synthases (iNOS), with subsequent autooxidation resulting in
formation of nitrate and nitrite (40). P. aeruginosa is capable of detoxifying these RNS
and actively uses them for respiration and macromolecule biosynthesis, thriving under
challenging conditions.
With induction of nirA under the control of HCN, maximal expression will occur
under microaerobic conditions due to the dual action of Anr and the las/rhl quorum-
sensing cascade (41). This suggests that NirA plays a similar role to NirBD of M. tubercu-
losis, allowing persistence or growth in vivo by protecting P. aeruginosa from nitrative
stress under oxygen limiting conditions. Work is now ongoing to understand the role
of NirA in virulence and how this overlaps with the function of NirBD, NirS, and
cyanogenesis.
While the mechanisms are yet to be unraveled, the discovery that the nitrite reduc-
tase NirA is required for virulence in multiple infection models represents a very attrac-
tive prospect for the development of inhibitors. Humans do not reduce nitrate and ni-
trite and as such do not encode nitrite reductases, minimizing off-site effects of any
inhibitors developed. Taking these points together makes NirA a promising antiviru-
lence target candidate against P. aeruginosa infections.
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Bacterial strains, plasmids, growth conditions, and DNA manipulation. Bacterial strains and plas-
mids are listed in Table S1 in the supplemental material. P. aeruginosa and E. coli were routinely cultured
in lysogeny broth (LB) at 37°C with vigorous shaking (200 rpm), unless otherwise stated. Artificial sputum
medium (ASM) was made according to reference 42, modified with the addition of 0.5mM KNO3 to repli-
cate conditions reported in the cystic fibrosis (CF) lung (43, 44). Media were solidified with 1.5% agar.
Antibiotics were added, when required, at concentrations of 20mgml21 for gentamicin, 15mgml21 for
nalidixic acid, and 20mgml21for streptomycin. Tetracycline was added at a final concentration of
150mgml21 for P. aeruginosa and 10mgml21 for E. coli. Protein overexpression was performed in terrific
broth (TB) (24 g/liter yeast extract, 12 g/liter tryptone, 4% glycerol, 0.017 M KH2PO4, and 0.072 K2HPO4)
supplemented with 1mM FeSO4·6H2O and 50mgml21 of carbenicillin and streptomycin.
Genomic DNA isolation was performed using a Wizard Genomic DNA purification kit (Promega).
Plasmid isolation was performed with GenElute plasmid miniprep kit (Sigma). All other standard DNA
manipulation techniques such as analysis, digestion, ligation, and transformation were performed
according to Sambrook and Russell (45).
Mutant selection and phenotype confirmation. A previously reported P. aeruginosa Tn5 mutant
library was further screened for new mutants showing alterations in pyocyanin production, swarming
motility, and alkaline protease activity with the aid of Flexis (Genomics solutions) colony-picking robot
as previously described (23). Quantitative assays confirming observed phenotypes for pyocyanin, pyo-
verdine, swarming, and protease were evaluated as described elsewhere (46).
C. elegans and D. melanogaster virulence assays. Both nematode slow killing assays and D. mela-
nogaster disease models were performed as previously described (23, 47).
Cell culture, IL-8 secretion, invasion, and cytotoxicity assays. A549 (human type II pneumocytes)
were purchased from ATCC and cultured as described previously (48). IL-8 secretion was performed as
reported previously (23). Bacterial invasion was determined using a polymyxin B protection assay (23).
Cytotoxicity of P. aeruginosa culture supernatant and cell pellet was assessed using the Syto-13/propi-
dium iodide viability test according to reference 49.
In-frame deletion mutant construction and complementation. To construct an in-frame deletion
in PA4130, two DNA fragments 427 bp upstream and 433bp downstream from PA4130 were generated
and fused by overlap extension PCR using PAO1-L genomic DNA as a template. The upstream 427-bp
fragment was amplified with primers PA4130F1 which carries an XbaI restriction site and PA4130R1 con-
taining the first 12 nucleotides of PA4130 with an overhanging end containing the last 15 nucleotides of
the PA4130 ORF (Table S1); the downstream 433-bp fragment was amplified with PA4130F2 containing
the last 15 nucleotides of PA4130 with an overhanging end containing the first 12 nucleotides and
PA4130R2 containing a HindIII restriction site (Table S1). To perform the overlap extension PCR, a sec-
ondary PCR was performed with the 427-bp and 433-bp fragments serving as the templates and primers
PA4130F1/PA4130R2 (Table S2). The final PCR product was cloned using the XbaI/HindIII restriction sites
into the vector pME3087, resulting in the suicide plasmid pME4130. The suicide plasmid used to gener-
ate the PA4129 mutant was constructed as described above, using primer pairs PA4129F1/PA4129R1
and PA4129F2/PA4129R2 to generate two PCR products upstream and downstream of PA4129 and
using primer pairs PA4129F1/PA4129R2 to generate the final PCR product containing a deletion in
PA4129, which was cloned into pME3087, resulting in the suicide plasmid pME4129 (Table S2).
The PA4129 and PA4130 in-frame deletions were generated by allelic exchange using pME4129 and
pME4130, respectively. Briefly, pME4129 and pME4130 were mobilized by conjugation into the relevant
P. aeruginosa strains using E. coli S17.1 lpir. Conjugants were selected for on LB agar supplemented
with tetracycline and nalidixic acid. Strains were restreaked twice on LB, with no antibiotic, and sub-
jected to tetracycline sensitivity enrichment to select for double crossover events (49). Colonies were
screened for loss of resistance to tetracycline with allelic exchange confirmed with PCR and DNA
sequencing, resulting in strains PASF06 (DPA4129), PAJD25 (PAO1-L DPA4130), PA7 Bo599 DPA4130,
PA14 AUS471 DPA4130, and LESB58 DPA4130 (Table S2).
Strain PAJD25 was complemented by amplifying a 2,172-bp fragment containing the PA4130 open
reading frame (ORF) and 1498 bp of the translational start site using primers 4130CTXF1/4130CTXR1.
The PCR product was cloned into the integrative vector mini-CTX-1 using the HindIII/BamHI restriction
sites, forming pCTX4130, with the resulting vector mobilized by conjugation, as performed with
pME4129 and pME4130. Conjugants were selected on LB agar supplemented with tetracycline and nali-
dixic acid. The integration of pCTX4130 was confirmed using PCR and DNA sequencing with comple-
mentation demonstrated through restoration of pyocyanin production and swarming motility.
Acute murine infection model. C57BL/6NCrlBR male mice (8 to 10weeks of age) were purchased
from Charles River Laboratories, Italy. In the acute murine lung infection model, P. aeruginosa strains
were grown for 3 h in tryptic soy broth (TSB). Bacteria were then harvested, washed twice with sterile
phosphate-buffered saline (PBS), and resuspended in sterile PBS to the desired dose for infection of
5 106 CFU/mouse. Mice were anaesthetized, and the trachea were directly visualized by a ventral mid-
line incision, exposed, and intubated with a sterile, flexible 22-g cannula attached to a 1-ml syringe
accordingly to established procedures (48). A 60-ml inoculum of 5 106 CFU was implanted into the
lung via cannula. Following infection, mice were monitored twice a day for 4 days. Mice that lost .20%
body weight and presented signs of severe clinical disease were sacrificed by CO2 administration before
termination of the experiment. Further details are outlined in supplemental material.
Agar bead infection model. C57BL/6 male mice (6 to 10weeks of age) were purchased from
Charles River Laboratories, Germany. The agar bead mouse model was performed according to estab-
lished procedures (50). Fresh cultures were prepared in 5ml TSB and incubated for 3 h. Bacterial cells
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were harvested and embedded in agar beads according to Bragonzi and colleagues (51). Five to 10 mice
were used for experiments and intratracheally infected with 4.6 106 CFU. Following infection, mice were
monitored twice a day for 2days. Mice that lost .20% body weight and presented signs of severe clinical
disease were sacrificed by injection of 2ml of 20% pentobarbital. For quantitative bacteriology, lung, liver,
and spleen were excised aseptically and homogenized using the homogenizer DIAX 900 (Heidolph GmbH,
Schwabach, Germany). Bacterial numbers in the organs were determined by 10-fold serial dilutions of the
homogenates, spotted onto blood plates after incubation at 37°C for 18 h.
Ethics statement. Acute murine infection studies were conducted according to protocols approved
by the San Raffaele Scientific Institute (Milan, Italy) Institutional Animal Care and Use Committee (IACUC)
and adhered strictly to the Italian Ministry of Health guidelines for the use and care of experimental ani-
mals. Agar bead infection studies were conducted according to protocols approved by Institute of
Medical Microbiology and Hygiene (Tübingen, Germany) and adhered strictly to guidelines set by the
German Ministry of Health and Animal Welfare Institute (Baden-Württemberg).
PA4130 expression and purification. The PA4130 orf was amplified from PAO1 genomic DNA using
primer pair NT4130F1/NT4130R1 containing N-terminal hexahistidyl tag and EcoRI/SacI restriction sites
(Table S2). The modified PA4130 fragment was cloned into vector pSK67 using EcoRI/SacI restriction
sites, resulting in plasmid pSK4130-N. The cysG orf was PCR amplified from E. coli BL21(DE3) using primer
pair CDFcysGF1/CDFcysGR1 containing restriction sites BglII/XhoI (Table S2). The modified cysG gene
was inserted into vector PCDF-DUET1 using restriction sites BglII/XhoI, producing vector pCDF-cysG. The
resulting pSK4130-N and pCDF-cysG coding sequences were confirmed with commercial Sanger
sequencing.
Vectors pSK4130-N and pCDF-cysG were cotransformed into E. coli NiCo21 by electroporation with si-
multaneous selection of both vectors on LB agar plates using carbenicillin and streptomycin. Single colo-
nies were selected and grown in LB broth for 16 h at 37°C. Cell density was then adjusted to an optical
density (OD) of 0.05 into TB and further grown to an OD of ;0.6 to 0.8 (600 nm). Cultures were then
cooled to 20°C before addition of 0.05 M ferric citrate and induction with 0.1mM isopropyl-b-D-thioga-
lactopyranoside. Following a further 18-h growth, cell pellets were harvested via centrifugation, flash fro-
zen in liquid N2, and stored at 280°C.
For purification, a combination of immobilized metal ion affinity chromatography (IMAC), chitin col-
umn chromatography (CCC) used to obtain soluble PA4130. Frozen pellets were resuspended in lysis
buffer consisting of 50mM Tris-HCl, 150mM NaCl, 1.2mg/ml lysozyme, and cOmplete Ultra EDTA-free
protease inhibitor cocktail at pH 8.0 with 1 g cell paste per 10ml of buffer. Samples were incubated on
ice for ;30 min with membrane disruption achieved by sonication (Fisher model 505/705).
IMAC was performed with the HiTrap chelating HP column (GE Healthcare) charged with NiSO4. The
column was equilibrated with 10 column volumes (CV) of buffer A containing 50mM Tris-HCl, 500mM
NaCl, 5% glycerol, 20mM imidazole at pH 8.0 before sample application with a peristaltic pump (GE
Healthcare model P1). PA4130 was obtained using a linear imidazole gradient from 20 to 400 mM imid-
azole between buffer A and buffer B (buffer A with 400mM imidazole) with red/brown samples collected
and pooled together.
Following IMAC, samples were processed and applied to chitin resin according to the manufacturer’s
instructions (New England Biolabs). The CCC flowthrough harboring PA4130 was collected and analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for homogeneity. For size-
exclusion chromatography, samples were concentrated to 5ml using a Vivaspin centrifugal filter unit
(Cytiva) and injected onto a 16/600 Superdex 200-pg column (Cytiva) and eluted with 50mM Tris and
150mM NaCl (pH 7.5).
Reduced methyl viologen assay. The PA4130 protein was tested for nitrite/sulfite reductase activity
using the artificial electron donor methyl viologen (MV); the MV reduction reaction in the presence of so-
dium dithionite produces a blue coloration. The assay was adapted from an assay of Schnell and col-
leagues (25) under anaerobic conditions to prevent oxygen-dependent oxidation of MV. MV oxidation
was tracked spectrophotometrically at 5-s intervals with nitrite, hydroxylamine, or sulfite acting as an
electron acceptor.
Griess diazotization and ammonia detection assays. Griess diazotization was performed using the
Griess reagent system (Promega) according to manufacturer’s instructions. The assays were performed
as described above, with the exception that the electron donors were altered. MV, spinach ferredoxin,
and NADPH plus flavin mononucleotide (FMN) were used, with MV and ferredoxin artificially reduced
using sodium dithionite. Temporal tracking of reduction reaction was achieved via sacrifice of eight in-
dependent reactions every 30 s.
Production of ammonia was confirmed using an ammonia assay kit (Sigma) according to the manu-
facturer’s instructions.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, PDF file, 0.1 MB.
FIG S2, PDF file, 0.1 MB.
FIG S3, PDF file, 0.1 MB.
FIG S4, PDF file, 0.01 MB.
TABLE S1, DOCX file, 0.1 MB.
TABLE S2, DOCX file, 0.1 MB.
Fenn et al. ®
March/April 2021 Volume 12 Issue 2 e00207-21 mbio.asm.org 12
 on A








TABLE S3, DOCX file, 0.04 MB.
TABLE S4, DOCX file, 0.05 MB.
ACKNOWLEDGMENTS
This study was supported by European Commission (grant NABATIVI, EU-FP7-
HEALTH-2007-B, contract number 223670), Wellcome Trust AAMR DTP program (grant
108876/Z/15/Z), and Ministero della Salute (project GR/2009/1579812). M.C. and P.W.
are partly funded by the National Biofilms Innovation Centre (NBIC) which is an
Innovation and Knowledge Centre funded by the Biotechnology and Biological
Sciences Research Council, InnovateUK, and Hartree Centre (award number BB/
R012415/1).
We especially thank Annika Schmidt for her help in obtaining data from the lab of
the late Gerd Döring. Her efforts have been invaluable in ensuring that the work of his
lab and its previous members continues to gain the recognition it deserves.
REFERENCES
1. Gellatly SL, Hancock RE. 2013. Pseudomonas aeruginosa: new insights
into pathogenesis and host defenses. Pathog Dis 67:159–173. https://doi
.org/10.1111/2049-632X.12033.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld
M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update
from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12.
https://doi.org/10.1086/595011.
3. Harmsen M, Yang L, Pamp SJ, Tolker-Nielsen T. 2010. An update on Pseu-
domonas aeruginosa biofilm formation, tolerance, and dispersal. FEMS
Immunol Med Microbiol 59:253–268. https://doi.org/10.1111/j.1574-695X
.2010.00690.x.
4. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front
Microbiol 2:65. https://doi.org/10.3389/fmicb.2011.00065.
5. World Health Organization. 2017. Prioritization of pathogens to guide dis-
covery, research and development of new antibiotics for drug-resistant
bacterial infections, including tuberculosis. World Health Organization,
Geneva, Switzerland.
6. Fernebro J. 2011. Fighting bacterial infections—future treatment
options. Drug Resist Updat 14:125–139. https://doi.org/10.1016/j.drup
.2011.02.001.
7. Bender KO, Garland M, Ferreyra JA, Hryckowian AJ, Child MA, Puri AW,
Solow-Cordero DE, Higginbottom SK, Segal E, Banaei N, Shen A,
Sonnenburg JL, Bogyo M. 2015. A small-molecule antivirulence agent for
treating Clostridium difficile infection. Sci Transl Med 7:306ra148. https://
doi.org/10.1126/scitranslmed.aac9103.
8. D’Angelo F, Baldelli V, Halliday N, Pantalone P, Polticelli F, Fiscarelli E,
Williams P, Visca P, Leoni L, Rampioni G. 2018. Identification of FDA-
approved drugs as antivirulence agents targeting the pqs quorum-sens-
ing system of Pseudomonas aeruginosa. Antimicrob Agents Chemother
62:e01296-18. https://doi.org/10.1128/AAC.01296-18.
9. Kong C, Neoh HM, Nathan S. 2016. Targeting Staphylococcus aureus tox-
ins: a potential form of anti-virulence therapy. Toxins (Basel) 8:72. https://
doi.org/10.3390/toxins8030072.
10. Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP,
Lopez-Ribot JL. 2017. Development of anti-virulence approaches for can-
didiasis via a novel series of small-molecule inhibitors of Candida albicans
filamentation. mBio 8:e01991-17. https://doi.org/10.1128/mBio.01991-17.
11. Smith KM, Bu Y, Suga H. 2003. Induction and inhibition of Pseudomonas
aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol
10:81–89. https://doi.org/10.1016/s1074-5521(03)00002-4.
12. Soukarieh F, Vico Oton E, Dubern JF, Gomes J, Halliday N, de Pilar
Crespo M, Ramirez-Prada J, Insuasty B, Abonia R, Quiroga J, Heeb S,
Williams P, Stocks MJ, Camara M. 2018. In silico and in vitro-guided
identification of inhibitors of alkylquinolone-dependent quorum sens-
ing in Pseudomonas aeruginosa. Molecules 23:257. https://doi.org/10
.3390/molecules23020257.
13. Maura D, Ballok AE, Rahme LG. 2016. Considerations and caveats in anti-
virulence drug development. Curr Opin Microbiol 33:41–46. https://doi
.org/10.1016/j.mib.2016.06.001.
14. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ,
Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L,
Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger
KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT,
Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome
sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.
Nature 406:959–964. https://doi.org/10.1038/35023079.
15. Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman FS. 2016.
Enhanced annotations and features for comparing thousands of Pseudo-
monas genomes in the Pseudomonas genome database. Nucleic Acids
Res 44:D646–D653. https://doi.org/10.1093/nar/gkv1227.
16. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM.
1995. Common virulence factors for bacterial pathogenicity in plants
and animals. Science 268:1899–1902. https://doi.org/10.1126/science
.7604262.
17. Finlay BB. 1999. Bacterial disease in diverse hosts. Cell 96:315–318.
https://doi.org/10.1016/s0092-8674(00)80544-9.
18. Tan MW, Mahajan-Miklos S, Ausubel FM. 1999. Killing of Caenorhabditis
elegans by Pseudomonas aeruginosa used to model mammalian bacte-
rial pathogenesis. Proc Natl Acad Sci U S A 96:715–720. https://doi.org/10
.1073/pnas.96.2.715.
19. Apidianakis Y, Rahme LG. 2009. Drosophila melanogaster as a model host
for studying Pseudomonas aeruginosa infection. Nat Protoc 4:1285–1294.
https://doi.org/10.1038/nprot.2009.124.
20. Chieda Y, Iiyama K, Yasunaga-Aoki C, Lee JM, Kusakabe T, Shimizu S.
2005. Pathogenicity of gacA mutant of Pseudomonas aeruginosa PA01 in
the silkworm, Bombyx mori. FEMS Microbiol Lett 244:181–186. https://doi
.org/10.1016/j.femsle.2005.01.032.
21. Koch G, Nadal-Jimenez P, Cool RH, Quax WJ. 2014. Assessing Pseudomo-
nas virulence with nonmammalian host: Galleria mellonella. Methods Mol
Biol 1149:681–688. https://doi.org/10.1007/978-1-4939-0473-0_52.
22. Clatworthy AE, Lee JS, Leibman M, Kostun Z, Davidson AJ, Hung DT. 2009.
Pseudomonas aeruginosa infection of zebrafish involves both host and
pathogen determinants. Infect Immun 77:1293–1303. https://doi.org/10
.1128/IAI.01181-08.
23. Dubern JF, Cigana C, De Simone M, Lazenby J, Juhas M, Schwager S,
Bianconi I, Doring G, Eberl L, Williams P, Bragonzi A, Camara M. 2015. Inte-
grated whole-genome screening for Pseudomonas aeruginosa virulence
genes using multiple disease models reveals that pathogenicity is host
specific. Environ Microbiol 17:4379–4393. https://doi.org/10.1111/1462
-2920.12863.
24. Wu JY, Siegel LM, Kredich NM. 1991. High-level expression of Escherichia
coli NADPH-sulfite reductase: requirement for a cloned cysG plasmid to
overcome limiting siroheme cofactor. J Bacteriol 173:325–333. https://doi
.org/10.1128/jb.173.1.325-333.1991.
25. Schnell R, Sandalova T, Hellman U, Lindqvist Y, Schneider G. 2005. Siro-
heme- and [Fe4-S4]-dependent NirA from Mycobacterium tuberculosis is
a sulfite reductase with a covalent Cys-Tyr bond in the active site. J Biol
Chem 280:27319–27328. https://doi.org/10.1074/jbc.M502560200.
26. Ramirez JM, Del Campo FF, Paneque A, Losada M. 1966. Ferredoxin-nitrite
reductase from spinach. Biochim Biophys Acta 118:58–71. https://doi.org/
10.1016/s0926-6593(66)80144-3.
NirA Is Required for Pseudomonas aeruginosa Virulence ®
March/April 2021 Volume 12 Issue 2 e00207-21 mbio.asm.org 13
 on A








27. Frangipani E, Perez-Martinez I, Williams HD, Cherbuin G, Haas D. 2014. A
novel cyanide-inducible gene cluster helps protect Pseudomonas aerugi-
nosa from cyanide. Environ Microbiol Rep 6:28–34. https://doi.org/10
.1111/1758-2229.12105.
28. Sparacino-Watkins C, Stolz JF, Basu P. 2014. Nitrate and periplasmic ni-
trate reductases. Chem Soc Rev 43:676–706. https://doi.org/10.1039/
c3cs60249d.
29. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, Miyata S, Diggins LT,
He J, Saucier M, Deziel E, Friedman L, Li L, Grills G, Montgomery K,
Kucherlapati R, Rahme LG, Ausubel FM. 2006. Genomic analysis reveals
that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol 7:
R90. https://doi.org/10.1186/gb-2006-7-10-r90.
30. Freschi L, Bertelli C, Jeukens J, Moore MP, Kukavica-Ibrulj I, Emond-
Rheault JG, Hamel J, Fothergill JL, Tucker NP, McClean S, Klockgether J, de
Soyza A, Brinkman FSL, Levesque RC, Winstanley C. 2018. Genomic char-
acterisation of an international Pseudomonas aeruginosa reference panel
indicates that the two major groups draw upon distinct mobile gene
pools. FEMS Microbiol Lett https://doi.org/10.1093/femsle/fny120.
31. Rojo F. 2010. Carbon catabolite repression in Pseudomonas: optimizing
metabolic versatility and interactions with the environment. FEMS Micro-
biol Rev 34:658–684. https://doi.org/10.1111/j.1574-6976.2010.00218.x.
32. Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD. 2013.
Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis
chronic lung infections. Environ Microbiol 15:398–408. https://doi.org/10
.1111/j.1462-2920.2012.02840.x.
33. Arai H. 2011. Regulation and function of versatile aerobic and anaerobic
respiratory metabolism in Pseudomonas aeruginosa. Front Microbiol
2:103. https://doi.org/10.3389/fmicb.2011.00103.
34. Moreno-Vivian C, Cabello P, Martinez-Luque M, Blasco R, Castillo F. 1999.
Prokaryotic nitrate reduction: molecular properties and functional distinc-
tion among bacterial nitrate reductases. J Bacteriol 181:6573–6584.
https://doi.org/10.1128/JB.181.21.6573-6584.1999.
35. Van Alst NE, Picardo KF, Iglewski BH, Haidaris CG. 2007. Nitrate sensing
and metabolism modulate motility, biofilm formation, and virulence in
Pseudomonas aeruginosa. Infect Immun 75:3780–3790. https://doi.org/
10.1128/IAI.00201-07.
36. Van Alst NE, Wellington M, Clark VL, Haidaris CG, Iglewski BH. 2009. Nitrite
reductase NirS is required for type III secretion system expression and vir-
ulence in the human monocyte cell line THP-1 by Pseudomonas aerugi-
nosa. Infect Immun 77:4446–4454. https://doi.org/10.1128/IAI.00822-09.
37. Romeo A, Sonnleitner E, Sorger-Domenigg T, Nakano M, Eisenhaber B,
Blasi U. 2012. Transcriptional regulation of nitrate assimilation in Pseudo-
monas aeruginosa occurs via transcriptional antitermination within the
nirBD-PA1779-cobA operon. Microbiology (Reading) 158:1543–1552.
https://doi.org/10.1099/mic.0.053850-0.
38. Akhtar S, Khan A, Sohaskey CD, Jagannath C, Sarkar D. 2013. Nitrite reduc-
tase NirBD is induced and plays an important role during in vitro dor-
mancy of Mycobacterium tuberculosis. J Bacteriol 195:4592–4599.
https://doi.org/10.1128/JB.00698-13.
39. Nathan C, Shiloh MU. 2000. Reactive oxygen and nitrogen intermediates
in the relationship between mammalian hosts and microbial pathogens.
Proc Natl Acad Sci U S A 97:8841–8848. https://doi.org/10.1073/pnas.97
.16.8841.
40. Sohaskey CD, Wayne LG. 2003. Role of narK2X and narGHJI in hypoxic up-
regulation of nitrate reduction by Mycobacterium tuberculosis. J Bacteriol
185:7247–7256. https://doi.org/10.1128/jb.185.24.7247-7256.2003.
41. Pessi G, Haas D. 2000. Transcriptional control of the hydrogen cyanide
biosynthetic genes hcnABC by the anaerobic regulator ANR and the quo-
rum-sensing regulators LasR and RhlR in Pseudomonas aeruginosa. J Bac-
teriol 182:6940–6949. https://doi.org/10.1128/jb.182.24.6940-6949.2000.
42. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C.
2012. Use of artificial sputum medium to test antibiotic efficacy against
Pseudomonas aeruginosa in conditions more relevant to the cystic fibro-
sis lung. J Vis Exp 2012:e3857. https://doi.org/10.3791/3857:e3857.
43. Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F.
1998. Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis
Child 78:49–53. https://doi.org/10.1136/adc.78.1.49.
44. Palmer KL, Aye LM, Whiteley M. 2007. Nutritional cues control Pseudomo-
nas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol
189:8079–8087. https://doi.org/10.1128/JB.01138-07.
45. Sambrook JF, Russell SA. 2001. Molecular cloning: a laboratory manual,
3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
46. Essar DW, Eberly L, Hadero A, Crawford IP. 1990. Identification and charac-
terization of genes for a second anthranilate synthase in Pseudomonas
aeruginosa: interchangeability of the two anthranilate synthases and evo-
lutionary implications. J Bacteriol 172:884–900. https://doi.org/10.1128/jb
.172.2.884-900.1990.
47. Lore NI, Cigana C, De Fino I, Riva C, Juhas M, Schwager S, Eberl L, Bragonzi
A. 2012. Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa
reduces virulence in multiple infection hosts. PLoS One 7:e35648. https://
doi.org/10.1371/journal.pone.0035648.
48. Pirone L, Bragonzi A, Farcomeni A, Paroni M, Auriche C, Conese M,
Chiarini L, Dalmastri C, Bevivino A, Ascenzioni F. 2008. Burkholderia ceno-
cepacia strains isolated from cystic fibrosis patients are apparently more
invasive and more virulent than rhizosphere strains. Environ Microbiol
10:2773–2784. https://doi.org/10.1111/j.1462-2920.2008.01697.x.
49. Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B,
Schumacher U, Grapler-Mainka U, Riethmuller J, Jensen PO, Bjarnsholt T,
Hoiby N, Bellon G, Doring G. 2010. Relative contribution of Prevotella
intermedia and Pseudomonas aeruginosa to lung pathology in airways of
patients with cystic fibrosis. Thorax 65:978–984. https://doi.org/10.1136/
thx.2010.137745.
50. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu
O, Givskov M, Johansen HK, Hoiby N. 2005. Novel mouse model of chronic
Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect
Immun 73:2504–2514. https://doi.org/10.1128/IAI.73.4.2504-2514.2005.
51. Bragonzi A, Worlitzsch D, Pier GB, Timpert P, Ulrich M, Hentzer M,
Andersen JB, Givskov M, Conese M, Doring G. 2005. Nonmucoid Pseudo-
monas aeruginosa expresses alginate in the lungs of patients with cystic
fibrosis and in a mouse model. J Infect Dis 192:410–419. https://doi.org/
10.1086/431516.
Fenn et al. ®
March/April 2021 Volume 12 Issue 2 e00207-21 mbio.asm.org 14
 on A
pril 27, 2021 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
